CLINICAL TRIALS IN RUSSIA

RESEARCH REPORT

CLINICAL TRIALS IN RUSSIA

ANNUAL 2018

SYNERGY ORANGE PAPER

? SYNERGY RESEARCH GROUP

WWW.

FOREWORD

The Orange Paper is a free publication produced by Synergy Research Group for the pharmaceutical industry since 2007. It pulls together data from numerous public sources into a single brief document to aid decision makers planning to conduct clinical trials. It is produced quarterly, with an annual summary at the close of each year.

SYNERGY ORANGE PAPER

TABLE OF CONTENTS

Executive Summary

Clinical Trials in Russia in Y 2018 ? Trial Data

Absolute numbers and per cent change of trials by type, phase and therapy area

? Sponsor Data

Absolute numbers and per cent change in number of subjects, breakdown by study type, phase and therapy area

? Patient Data

Absolute numbers and per cent change in number of subjects, breakdown by study type, phase and therapy area

? Site Data

Top performing sites, breakdown into BE & Phase I, Phase II-III and Phase IV

? CRO Data

Top Five CROs by absolute number of new studies.

? Regulatory & Inspection Data

New drugs approved by FDA and EMA with Russian sites, update on Regulatory changes and CTA timelines.

SYNERGY ORANGE PAPER

EXECUTIVE SUMMARY

During the year 2018 the Ministry of Health of the Russian Federation approved the start of 653 new clinical trials of all types, with an overall year on year decline of 6,7% by total number of studies.

The dominant type of clinical trials conducted in Russian sites during 2018 were MMCT (Multinational Multi-center Clinical Trials) with 44% market share. The most prevalent Phase of clinical trials conducted in Russian sites by total number of studies was Phase III.

There is a significant level of oligopoly within the Russian Clinical trials market ? with the top-10 International Sponsors accounting for 24% of the total number of studies conducted, and for 25% of all patients enrolled during the year 2018. The top-10 Russian sponsors take up approximately 9% of the market by total number of trials conducted, and have 15% of all patients enrolled in these trials. The twenty largest pharmaceutical companies combined account for 33% of all clinical trials and for 40% of all patients enrolled.

During Y 2018 the Center for Drug Evaluation and Research (CDER) of the U.S. FDA approved 162 new drugs, including new molecular entities (NME), new dosages, combinations or manufacturers. Fourteen of these drugs were tested (or being studied) in clinical trials involving Russian sites.

In Y 2018 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) evaluated 78 new drugs, including 16 generics and 6 biosimilar drugs. 70 of these drugs received positive opinions and were approved for marketing. 43 of the approved drugs were tested (or being studied) in clinical trials involving Russian sites.

The top-5 domestic pharmaceutical manufacturers in Russia during 2018 were Microgen, Biocad, Valenta Pharmaceuticals, Materia Medica Holding and Petrovax Pharma.

The top-5 International Sponsors in Russia during 2018 were Novartis, Roche, Janssen, Pfizer and AstraZeneca.

According to the U.S. FDA data, there were no FDA inspections conducted at Russian investigative sites during 2018; 300 FDA inspections were conducted at U.S. investigative sites, and 38 FDA inspections were conducted at investigative sites located in the 18 leading European countries. European countries receiving the most inspections were Poland (9 inspections), Germany (6 inspections) and France (5 inspections).

CLINICAL TRIALS IN RUSSIA. ANNUAL 2018

SYNERGY ORANGE PAPER

CLINICAL TRIALS IN RUSSIA

Trial Data

During the year 2018 the Ministry of Health of the Russian Federation approved the start of 653 new clinical trials of all types, including local and bioequivalence studies. This represents a 6,7% year on year decline by the total number of studies.

The dominant type of clinical trials conducted across Russian sites in 2018 were MMCT (Multinational Multi-center Clinical Trials). The market share of MMCT climbed by 3% and is now at 44% of the total number of trials. The market share of LCT dipped by 4% down to 24%, and BE's share increased slightly from 31% to 32%.

700 653

Figure 2-2. Clinical trials in Russia in Y 2018

Total

291 289

194 158

215 206

MMCT

LCT

BE

Y 2017 Y 2018

CLINICAL TRIALS IN RUSSIA. ANNUAL 2018

SYNERGY ORANGE PAPER

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download